Clinical Trials Browser

Phase 1/2 × INDUSTRY × Thyroid Carcinoma, Anaplastic × Clear all

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT05102292 2023-08-21

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Phase 1/2 Unknown

25 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1/2 Completed

319 enrolled 41 charts

BreastDermatologicEndocrineHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Phase 1/2 Terminated

19 enrolled 13 charts

EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

Clinical Trials

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel